The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.

Abstract

This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.

Keywords: Biomarkers; Clinical trials; Diffuse large B‐cell lymphoma; Individual patient data; Meta‐database; Surrogate endpoints.

MeSH terms

  • Biomarkers / analysis*
  • Clinical Trials as Topic*
  • Endpoint Determination
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Meta-Analysis as Topic
  • Survival Rate
  • Treatment Outcome

Substances

  • Biomarkers